Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.
[Company Profile] Urovalve
Men with acute or chronic urinary retention find that the condition limits their normal activities, causes embarrassment, and poses serious health risks. Urovalve of Newark, NJ, seeks to replace catheterization with an updated treatment that returns bladder control to the patient.
Sen. Kennedy Death Puts Focus On Brain Cancer
Glioblastoma multiforme (GBM), the aggressive brain tumor that took Sen. Kennedy’s life, is one of the deadliest brain tumors that can occur in both adults and children.
NeoPharm Tipped As Stock to Watch
NeoPharm, a biopharmaceutical company developing drugs for cancer treatment, has been tipped as a worthwhile stock on financial website Seeking Alpha.
Positive Peer Review for Aureon’s Prostate Px+
The peer reviewed results published today in the Journal of Urology found that Aureon Laboratories’ Prostate Px+ test is twice as effective as other tools currently available at identifying which patients classified as intermediate-risk have high-risk, life-threatening cancer.
Aureon Featured In TV Segment
Aureon Laboratories, a developer of predictive tests for cancer care, has been featured in a cable television segment produced by the Yonkers Chamber of Commerce.
Clarient Files Registration Agreement With SEC
Clarient has filed a registration statement with the Securities and Exchange Commission on Form S-3 relating to shares of Clarient owned by Safeguard.
Clarient Launches New Gene Mutation Test for Lung Cancer
Clarient has launched a new gene mutation test to help physicians select the appropriate therapy for non-small cell lung cancer.
